Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 0.74 |
| ▸ | CA9 | Q16790 | 10/20 | 0.74 |
| ▸ | CA2 | P00918 | 6/20 | 0.74 |
| ▸ | CA1 | P00915 | 6/20 | 0.74 |
| ▸ | CA3 | P07451 | 5/20 | 0.74 |
| ▸ | CA4 | P22748 | 5/20 | 0.74 |
| ▸ | CA5A | P35218 | 5/20 | 0.74 |
| ▸ | CA7 | P43166 | 5/20 | 0.74 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.74 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.74 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.74 |
| ▸ | CA6 | P23280 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.74 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coumarin SCHEMBL3768564 | 0.92 | CA12 (0.80) | CA12CA9CA2CA1CA3 | |
| Coumarin SCHEMBL28826370 | 0.92 | CA9 (0.80) | CA12CA9CA2CA1CA3 | |
| Coumarin SCHEMBL28140387 | 0.89 | CA12 (0.74) | CA12CA9CA2CA1CA3 | |
| Coumarin SCHEMBL7106473 | 0.86 | CA12 (0.91) | CA12CA9CA2CA1CA3 | |
| Coumarin SCHEMBL25431834 | 0.86 | CA12 (0.91) | CA12CA9CA2CA1CA3 | |
| Coumarin SCHEMBL3441294 | 0.86 | CA12 (1.00) | CA12CA9CA2CA1CA3 | |
| Coumarin SCHEMBL28886137 | 0.86 | CA12 (1.00) | CA12CA9CA2CA1CA3 | |
| Coumarin SCHEMBL621751 | 0.86 | CA12 (1.00) | CA12CA9CA2CA1CA3 | |
| Coumarin SCHEMBL1038138 | 0.86 | CA12 (1.00) | CA12CA9CA2CA1CA3 | |
| Coumarin SCHEMBL29385611 | 0.86 | CA12 (1.00) | CA12CA9CA2CA1CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| EP-4540249-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | Yeda Research and Development Co. Ltd (IL) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023242845-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (CoLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-21 | — | — | WO | disclosed |
| EP-1996604-B1 | STEROIDAL COMPOUNDS AS STEROID SULPHATASE INHIBITORS | STERIX LTD (GB) | 2013-09-25 | — | — | EP | disclosed |
| US-8124614-B2 | Steroidal compounds for inhibiting steroid sulphatase | STERIX LIMITED (GB) | 2012-02-28 | — | — | US | disclosed |
| US-8003783-B2 | Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer | STERIX LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-7968561-B2 | Steroidal compounds as steroid sulphatase inhibitors | STERIX LIMITED (GB) | 2011-06-28 | — | — | US | disclosed |
| EP-2336146-A1 | 17beta-hydroxysteroid dehydrogenase inhibitors | Sterix Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-7846965-B2 | a non-steroidal sulphamate compound such as 6-Oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulphamate, suitable for use as an inhibitor of estrone sulphatase, for the treatment of endocrine-dependent cancers and tumors, such as the breast and endometrium | STERIX LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20050154050-A1 | Compound | REED MICHAEL J (GB) | 2005-07-14 | — | — | US | disclosed |
| US-20050014776-A1 | Steroidal compounds for inhibiting steroid sulphatase | RICHTER GEDEON NYRT. (HU) | 2005-01-20 | — | — | US | disclosed |
| WO-2004085457-A2 | 17BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
| EP-1448592-A1 | STEROIDAL COMPOUNDS FOR INHIBITING STEROID SULPHATASE | Sterix Limited (GB) | 2004-08-25 | — | — | EP | disclosed |
| EP-1385991-A2 | ISOLATED HUMAN ENZYME PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN ENZYME PROTEINS, AND USES THEREOF | PE Corporation (NY) (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003033518-A1 | STEROIDAL COMPOUNDS FOR INHIBITING STEROID SULPHATASE | STERIX LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| US-20030013167-A1 | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | APPLERA CORPORATION (US) | 2003-01-16 | — | — | US | disclosed |
| US-6461847-B1 | TO EFFECT PROTEIN PHOSPHORYLATION; FOR USE IN DIAGNOSIS AND THERAPY | APPLERA CORPORATION | 2002-10-08 | — | — | US | disclosed |
| WO-2002074974-A2 | ISOLATED HUMAN ENZYME PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN ENZYME PROTEINS, AND USES THEREOF | PE CORPORATON (NY) (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20020132294-A1 | ISOLATED HUMAN ENZYME PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN ENZYME PROTEINS, AND USES THEREOF | APPLIED BIOSYSTEMS, LLC | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | CA12 1385/4885CA9 1886/4885CA2 3402/4885 |
| US-20050014776-A1 | Steroidal compounds for inhibiting steroid sulphatase | STS, NR5A1, CYP21A2 | CA12 1851/4885CA9 578/4885CA2 1367/4885 |
| US-20050154050-A1 | Compound | HSD17B11, NR5A1, CYP17A1 | CA12 864/4885CA9 519/4885CA2 796/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | CA12 638/4885CA9 412/4885CA2 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.